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Abstract  Article Information 
A drug is a chemical substance used in the diagnosis, treatment or prevention of disease 
or as a component of a medication, should be specific and freedom from side affect.  
Many issues should be addressed while designing a new drug or improving existing 
compound. The increase in the interdisciplinary nature of science gives bioinformatics, 
systems and computational biology, which helps in reducing research and development 
costs, minimize drug failures by predicting drug efficacy and toxicity. One of the most 
important pathogenic bacterium is Aeromonas species which causes tissue damage, 
acute gastroenteritis and neonatal septicemia. Bacterial proteins are the ultimate target to 
inhibit their growth and these are the executors of cellular function. In related to this we 
selected four such different proteins Flavohemo protein, Guanylate kinase, 
Topoisomerase and Oligopeptidase found to be present in both humans and Aeromonas 
to study the effects of antibiotics through in silico approaches. An attempt has been made 
to classify the inhibitors as host protein inhibitors or guest protein inhibitors. Finally we 
conclude that the molecule AgkI5 (2-morpholin-4-yl-thianthren-1-ylpyron-4-one) shown 
good inhibition with minimum binding energy -9.30, docking energy -10.03, inhibition 
constant 1.53e-007 and RMS 0.0 against Aeromonas Guanylate kinase  [Aeromonas: 
Modelled] when compared to human Guanylate kinase [PDB ID: 1KJD]. So AgkI5 was 
predicted as a good antibiotic against Aeromonas Species.    
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INTRODUCTION 
A drug, is any substance that, when absorbed into the 
body of a living organism, alters normal bodily function. In 
the field of pharmacology, a drug can be defined as a 
chemical substance used in the treatment, cure or 
prevention of disease otherwise used to enhance physical 
or mental well-being. Drugs must be not only effective but 
safe; side-effects can range from minor to dangerous. 
 
Humans have been Figurehting against bacterial 
pathogens for many decades. Since, then humans have 
been utilizing various chemical substances with 
antibacterial or bacteriostatic properties. In the past 50 
years, borrowing anti-bacterials from other bacteria and 
fungi even produced an impression of success in this 
battle (Galperin et al., 1999). 
 
The bactericidal antibiotic killing mechanisms are 
currently attributed to the class-specific drug-target 
interactions. Current antimicrobial therapies, which cover 
a wide array of targets, fall into two general categories: 
bactericidal drugs-which kill bacteria with an efficiency of 
>99.9% and bacteriostatic drugs- which merely inhibit 
growth (Michael et al., 2007). 
 
Bacteria belonging to Aeromonas species have been 
identified as common enteric pathogens from several 
countries. They cause acute gastroenteritis of both adults 
and children’s, ranging from watery to blood diarrhoea of 
either short or prolonged (over 2 weeks) duration. In 
mammals, Aeromonas species causes neonatal 
septicemia (Bharath and Manjunatha, 2013). They occur 
widely in the environment, especially in water. They are 
found in both raw and chlorinated water supplies (Kudinha 
et al., 2004). 
 
Aeromonas hydrophila, Aeromonas caviae, and 
Aeromonas sobria are all considered to be “opportunistic 
pathogens,” meaning they only infect hosts with 
weakened immune responses. Because of Aeromonas 
hydrophila’s structure, it is very toxic to many organisms. 
When it enters the body of its victim, it travels through the 
bloodstream to the first available organ. It produces 
Aerolysin Cytotoxic Enterotoxin (ACT), a toxin that can 
cause tissue damage (Chopra et al., 2000). Though 
Aeromonas hydrophila is considered a pathogenic 
bacterium, scientists not been able to prove that it is the 
actual cause of some of the diseases it is associated with. 
It is believed that this bacterium aids in the infection of 
diseases, but do not cause the diseases themselves.  
 
Foods have been implicated in the transmission of 
Aeromonas species. Motile Aeromonas have been 
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isolated from fresh foods of animal origin. The 
microorganism has the potential to be a food borne 
pathogens. The disease spectrum associated with these 
microorganisms includes gastroenteritis, Septicemia, 
aquatic wound infections (Kudinha et al., 2004). 
 
Proteins are the ultimate executors of cellular function, 
and thus are directly responsible for a biological 
phenotype (Anderson et al., 2002). Proteomics is the 
study of the expression, modification and activity of 
proteins in order to better understand a biological system. 
Diseased (or drug treated lysates) are identically 
processed and comparative analysis performed to 
evaluate protein expression between the two samples 
(Aebersold et al., 2003). So in the present study, we 
selected four different proteins present in both Aeromonas 
and human system they are Guanylate Kinase protein, 
Oligopeptidase protein, Flavohemoprotein and 
Topoisomerase protein by functional analysis we will 
come to know that whether the proteins are orthologs or 
not using molecular docking studies as the force field is 
based on the concept of residue- residue contact 
energies. Reduced structures can be translated to atomic 
resolution, and further evaluated (Andrzej et al., 2003). 
 
MATERIALS AND METHODS 
Sequence, structure and domain analysis was 
performed to predict the efficacy of inhibitor molecules 
against proteins. Protein sets were downloaded by Integr8 
database and protein families were studied in Interpro, 
and then BLAST was performed for protein sequences 
against PDB to verify about the availability of structural 
information. BLAST and Genius clustalW tools were 
employed for sequence analysis. Structure analysis was 
performed using PDB database and protein homology 
modeling was achieved in Swiss modeler and validated 
through ADIT validation server by plotting Ramachandran 
plot for some proteins whose structural information was 
not available in PDB, Topmatch server was used for 
protein superimposition. Domain analysis was performed 
for all the proteins using Prosite server. Molecular docking 
studies were done using AutoDock v3.0 for known 
inhibitors downloaded from PubChem against selected 
proteins. An attempt has been made to classify the 
inhibitors as human protein inhibitors or Aeromonas 
protein inhibitors. 
 
RESULTS AND DISCUSSION 
From the integr8, we have downloaded the proteomic 
sets of human and bacteria. Interpro IDs From that 
proteome set were taken and submitted for Interpro, 
which shows the protein family, out of them we have 
selected four families and cross referenced with Pfam 
database for confirmation and selected four below 
showed in Table 1. The protein sequences for Guanylate 
kinase, Oligopeptidase, Flavohemoprotein and DNA 
Topoisomerase with a Uniprot ID’s A0KEC4, A0KEG4, 
A0KG18 and A5UCC4 respectively in FASTA format were 
collected and subjected for sequence analysis.  
 
Table 1: The Pfam IDs for four proteins 
 
Protein Pfam ID 
Guanylate kinase PF00625 




Sequence Analysis  
psi-BLAST was performed for Flavohemoprotein, 
Guanylate kinase, Topoisomerase and Oligopeptidase 
protein sequences in FASTA format against non-
redundant database, and the sequences from different 
species from Human to bacteria were selected from the 
obtained hits (Stephen et al., 1997). The Multiple 
Sequence Alignment was performed for the selected 
sequences using T-coffee to analyze the conserved 
regions (Figure 1-4). 
 
Figure 1: Flavohemoprotein. 
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Figure 3: Topoisomerase. 
 
The BLAST against Non-Redundant Database was 
performed for the FASTA sequences, numbers of hits for 
same protein were obtained, we have selected these 
sequences from different species and the FASTA 
sequences were downloaded. For downloaded sequences 
we performed Multiple Sequence Alignment using Genius 
Pro. (Figure 1-4). Here conserved regions among 
Aeromonas, Human and other species were analyzed, by 
this MSA we can say that the proteins both in Human and 
Bacteria performs same functions due to the conservation 
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Figure 4: Oligopeptidase. 
 
Domain Analysis 
Domain analysis of these four proteins was done using 
PROSITE server. Here domains of Aeromonas protein are 
compared with the domains of human proteins. The 
domain hits obtained for Human guanylate kinase protein 
and Aeromonas Guanylate kinase sequences were 










respectively, this indicates the domain shifting. Human 
guanylate kinase was observed with five more domains 
such as PROTEIN KINASE_OOM, two L27 domains, PDZ 
and 3H3 domains which were not seen on Aeromonas 
sequence (Laurent et al., 2002). 
Figure 5a: Human Guanylate kinase. 
Figure 5b: Aeromonas Guanylate kinase  
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Similarly Oligopeptidase sequences were submitted 
and domain hits were obtained only for human sequence, 
no hits were found for bacterial sequence, and here we 
failed to observe the domain similarity between human 
and bacterial sequences. Neutral zinc metallopeptidases, 
zinc-binding region was observed on Human sequence as 
shown in Figure 6. 
 
Domain analysis of Flavohemoprotein has received 
single hit corresponding the pattern for electron transfer 
flavoprotein beta-subunit on Human sequence and two 
hits by two distinct profiles namely Globin and FAD_FR on 
Aeromonas sequence as shown in Figure 7a and b.  
 
In Topoisomerase domain analysis we observed the 
DNA topoisomerase II domain having eight amino acids 
length on both the sequences Figure: 8a and 8b, on 





 residue and on Aeromonas sequence the 
domain was from 416
th
 residue to 424
th
 residue. Here also 
we can observe the domain shifting as shown in Figure 8a 
and 8b.  













































Figure 8a: Human Topoisomerase. 
 

















Figure 8b: Aeromonas Topoisomerase. 
 
Structural Analysis 
By domain analysis, we came to know the changes in 
domain composition that may lead to the structural 
differences. So we performed structural analysis for all the 
4 proteins. For structural analysis we have collected the 
structures of proteins from PDB Table 1. We performed 
homology modeling using online modeling server Swiss 
model by taking E. coli structures as a template (Figure 
9). The modeled structures were validated by 
ramachandran plot given by ADIT we can say that our 
models are good. The numbers of residues in favored 
region were 92.0%, 91.4% and 92.1% for 
Flavohemoprotein, Guanylate kinase and Topoisomerase 
respectively (Denis et al., 2002). 
 
For structural similarity studies between Human and 
Aeromonas Protein structural superimposition was 
performed. The RMS values are 2.4, 3.3, 2.6 and 2.5 for 
Flavohemoprotein, Guanylate kinase, Topoisomerase and 
Oligopeptidase respectively as shown in Table 2. The 
modeled proteien structures were subjected for active 
pocket prediction, for PDB structures we referred ligplot 
provided by PDB only and for designed models castP 
server was used, the amino acids in active pockets are 
tabulated in Table 3. Even there is no complete structural 
similarity, domain similarity the proteins performing the 
same function in human and Aeromonas (Joe et al., 
2006). This led us for species specific targeting and an 
attempt was made to illustrate the targeting results by 
performing molecular docking studies. 
 
The protein structures of Aeromonas were 
superimposed against human protein structures using 
TOPMATCH server, and also RMS value is documented 
in Table 2 and we can observe the super imposition in the 
Figure 10. The active pockets on our PDB structures were 
identified by referring their ligplot and for designed models 




Figure 9: The protein structures of A: Aeromonas 
Flavohemoprotien, B: Human Flavohemoprotien, C: 
Aeromonas Guanylate kinase, D: Human Guanylate 
kinase, E: Aeromonas DNA Topoisomerase, F: 
Human DNA Topoisomerase, G: Aeromonas 
Oligopeptidase, H: Human DNA Oligopeptidase 
Table 2: Structure superimposition using TopMatch. 
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Table 3: Amino Acids in Active pocket. 







VAL-1, ALA-2, TYR-4, LYS-6, ASN-7, ALA-13, LEU-14, ALA-17, VAL-
18, ARG-20, ILE-21, LYS-24, HIS-25, GLY-27, PHE-28, LEU-29, ILE-
30, GLN-31, GLN-34, TYR-35, VAL-38, HIS-41, LEU-42, THR-45, LEU-
46, LEU-49,  TRP-62, ALA-65, TYR-66, LEU-69, ALA-70, PHE-73, 
SER-94, GLU-105, ILE-109, SER-111, TYR-130, SER-132, LYS-134, 
GLN-143, GLU-144, ILE-145, ARG-146, GLN-147, TYR-148, SER-149, 
ASP-152, ARG-160, SER-162, VAL-163, LYS-164, GLU-166, PRO-
167, GLN-168, GLY-169, GLN-170, VAL-171, SER-172, VAL-187, 
MET-188, ALA-209, GLY-210, VAL-211, GLY-212, ILE-213, THR-214, 
PRO-215, MET-217, SER-218, HIS-236, ALA-237, CYS-238, GLU-239, 
GLN-240, ALA-242, VAL-243, HIS-244, ALA-245, PHE-246, ARG-247, 
TYR-266, ARG-267, THR-284, GLY-304, PRO-305, VAL-306, PHE-
308, MET-309, GLN-310, LYS-313, GLN-314, ILE-317, ALA-323, TYR-






ASN-132, ALA-126, ASP-129, ASN39, CYS-42, GLY-123, ALA-9, THR-






SER-27, SER-28, PRO-29, SER-30, GLY-31, LYS-34, SER-35, LEU-
38, ASN-39, LEU-42, HIS-45, SER-47, MET-51, GLN-52, LEU-53, 
SER-54, VAL-55, SER-56, HIS-57, ARG-60, ARG-63, PRO-64, VAL-70, 
HIS-71, TYR-72, HIS-73, GLU-91, ALA-93, VAL-95, PHE-96, ASN-98, 
TYR-100, GLY-101, THR-102, SER-103, ALA-106, ILE-107, CYS-110, 
ILE-115, VAL-117, LEU-119, ASP-120, ILE-121, ASP-122, GLY-125, 
ARG-151, LEU-152, ILE-153, GLY-154, ARG-155, GLY-156, GLN-157, 










ASP-2, GLN-3, SER-4, LEU-5, GLU-6, VAL-7, ILE-8, ASP-9, ASP-10, 
GLY-11, ARG-12, GLY-13, MET-14, PRO-15, HIS-19, GLY-26, LEU-29, 
ILE-30, ALA-36, GLY-37, GLY-38, LYS-39, PHE-40, LYS-43, ASN-44, 
TYR-45, PHE-47, SER-48, GLY-49, GLY-50, LEU-51, HIS-52, GLY-53, 
VLA-54, GLY-55, ILE-56, SER-57, VAL-58, VAL-59, LEU-62, SER-63, 
ARG-72, THR-103, ARG-104, VAL-105, ARG-106, PHE-107, PRO-109, 
PHE-114, ASP-115, SER-116, PRO-117, ARG-118, PHE-119, SER-
120, VAL-121, SER-122, LYS-123, LEU-124, HIS-126, LEU-127, LEU-
128, ALA-130, LYS-131, ALA-132, CYS-135, LEU-138, THR-139, ILE-
140, LYS-141, PHE-142, LEU-143, ASP-144, LYS-145, ASN-146, THR-
147, GLU-201, TYR-207, ASN-209, LEU-210, ILE-211, PRO-212, ALA-






ARG-162, LYS-378, ASN-163, GLN-376, ASN-150, SER-148, ASN-91, 


































Figure 10: The super imposition protein structure from Aeromonas and Humans A: Flavohemoprotien, B: Guanylate 
kinase, C: DNA Topoisomerase, D: Oligopeptidase 
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Molecular Docking Studies  
The inhibitors of all the four proteins were downloaded 
from pubchem data base, name, structure ID, structure 
and LogP of all the inhibitors subjected for docking are 
tabulated in Table 4, 5, 6 and 7 for Flavohemoprotein 
inhibitors, Guanylate kinase inhibitors, Topoisomerase 
inhibitors and Oligopeptidase inhibitors respectively 
(Rajesh et al., 2013). Flavohemoprotein inhibitors (4 and 
8) and Oligopeptidase inhibitors (4 and 8) have not 
docked successfully. 
 
Table 4: Flavohemoprotein Inhibitors 
Mol. No Name of Structure Structure ID Structure Log P value 










naphthalen-1-yl N-methylcarbamate  
2.4 
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Table 5: Guanylate kinase inhibitor. 
 
Mol. No Name of Structure Structure ID Structure Log P value 


























PP1 cpd; tyrosine 

































In the Molecular docking study of Flavohemoprotein 
inhibitors against Human and Aeromonas 
Flavohemoprotein, the inhibitor HfhI9 showed minimum 
docking energy, binding energy, inhibition constant and 
0.92 RMS value with Human Flavohemoprotein (Figure 
11). The same molecule named AfhI9 showed minimum 
docking energy, binding energy, inhibition constant and 
0.0 RMS value against Aeromonas Flavohemoprotein but 
less when compare with HfhI9. The AfhI7 shown good 
results than other Aeromonas protein inhibitors (Figure 
12). This kind of inhibitors cannot use as an antibacterial 
drugs. The minimum binding energy, docking energy, 
Inhibition constant and RMS value are tabulated in Table 
8 and 9. 
Molecular docking study of Guanylate kinase inhibitors 
against Human and Aeromonas Guanylate kinase showed 
that the inhibitor HgkI5 showed minimum docking energy, 
binding energy, inhibition constant and 0.0 RMS value 
with Human Guanylate kinase protein (Figure 13). The 
same molecule named AgkI5 showed minimum docking 
energy, binding energy, inhibition constant and 0.0 RMS 
value against Aeromonas Guanylate kinase but less when 
compare with HgkI5. The AgkI5 inhibitor showed good 
results than HgkI5 (Figure.14). This kind of inhibitors can 
use as an antibacterial drugs. The minimum binding 
energy, docking energy, Inhibition constant and RMS 
value are tabulated in Table 10 and 11. 
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Table 6: Topoisomerase inhibitors 
 
Mol. No Name of Structure Structure ID Structure Log P value 












ylic acid  
-0.4 





































In the Molecular docking study of Topoisomerase 
inhibitors against Human and Aeromonas Topoisomerase, 
the inhibitor HtopI4 showed minimum docking energy, 
binding energy, inhibition constant and 0.0 RMS value 
with Human Topoisomerase (Figure 15). The same 
molecule named AtopI4 showed minimum docking 
energy, binding energy, inhibition constant and 0.0 RMS 
value against Aeromonas Topoisomerase but less when 
compare with HtopI4. The AtopI3 shown good results than 
other Aeromonas protein inhibitors (Figure 16). This kind 
of inhibitors cannot use as an antibacterial drugs. The 
minimum binding energy, docking energy, Inhibition 
constant and RMS value are tabulated in Table 12 and 
13. 
Eventually the molecular docking study of 
Oligopeptidase inhibitors against Human and Aeromonas 
Oligopeptidase was performed, here also the inhibitor 
HopI1 showed minimum docking energy, binding energy, 
inhibition constant and 0.0 RMS value with Human 
Oligopeptidase (Figure 17). The same molecule named 
AopI1 showed minimum docking energy, binding energy, 
inhibition constant and 0.0 RMS value against Aeromonas 
Oligopeptidase but less when compare with HopI1. The 
AopI1 shown good results than other Aeromonas protein 
inhibitors (Figure 18). This kind of inhibitors cannot use as 
an antibacterial drugs. The minimum binding energy, 
docking energy, Inhibition constant and RMS value are 
tabulated in Table 14 and 15. 
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Table 7: Oligopeptidase inhibitor. 
 
Mol. No Name of Structure Structure ID Structure Log P value 




































































































Figure 11:  Graph showing binding energy and Docking energy of an inhibitors with both Human and Aeromonas 
Flavohemoprotein. 
 
Figure 12: Docking of flavohemoprotein with the ligand flesinoxan, Top three corresponds to Aeromonas and Bottom 
three corresponds to human. 
 
Table 8: Docking results for Aeromonas Flavohemoprotein (modeled protein) 





































Table 9: Docking results for Human Flavohemoprotein (1EFV) 
 











































































Figure 13: Graph showing binding energy and docking energy of an inhibitors with both Human and Aeromonas 

























Figure 14: Docking of guanylate kinase with the ligand Nchembio.63-Comp3, Top three corresponds to Aeromonas and 
Bottom three corresponds to human Docking results. 
 
Table 10: Docking results for Aeromonas Guanylate kinase (Modeled). 
 




























Table 11: Docking results for Human Guanylate kinase (1KGD). 
 



























































              
Figure 15: Graph showing Binding energy and Docking energy of an inhibitors with both Human and Aeromonas 



























Figure 16:  Docking of DNA Topoisomerase with the ligand Ciprofloxacin, Top three corresponds to Aeromonas and 
Bottom three corresponds to human. 
 
Table 12: Docking results for Aeromonas Topoisomerase (Modeled) 
 






















Table 13: Docking results for Human Topoisomerase (1S16) 
 






















































Figure 18:  Docking of Oligopeptidase with the ligand Citalopram, Top three corresponds to Aeromonas and Bottom 
three corresponds to human. 
 
Table 14: Docking results for Aeromonas Oligopeptidase (2DEA) 
 





































Table 15: Docking results for Human Oligopeptidase (2DEA) 
 









































By the sequence analysis, structural analysis, and 
functional analysis of the four proteins taken from the 
human and bacteria, we have performed the docking 
studies by taking the inhibitors for four proteins. These 
inhibitors showed good docking energy with human 
proteins than Aeromonas hydrophila proteins which 
mediates neonatal septicemia, gastroenteritis and aquatic 
wound infections in mammals.  Thus, we conclude that 
the taken inhibitors cannot be used as antibiotics, but the 
AgkI5 inhibitor showed good results than HgkI5, this kind 
of inhibitors can be use as antibacterial drugs. 
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